Richard Paulson is President and Chief Executive Officer of Karyopharm Therapeutics Inc. (KPTI). The company reported total compensation of $2,320,902 for fiscal year 2025.
| Salary | $770,000 |
|---|---|
| Bonus | $100,100 |
| Stock awards | $838,996 |
| Option awards | $241,544 |
| Non-equity incentive plan | $350,350 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $19,912 |
| Total | $2,320,902 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Karyopharm Therapeutics Inc. filed April 13, 2026, accession 0001503802-26-000023.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $770,000 | $100,100 | $838,996 | $241,544 | $350,350 | $0 | $19,912 | $2,320,902 |
| FY2024 | President and Chief Executive Officer | $769,600 | $0 | $854,604 | $0 | $425,425 | $0 | $19,712 | $2,069,341 |
| FY2023 | President and Chief Executive Officer | $740,000 | $200,000 | $1,201,200 | $0 | $456,950 | $0 | $28,138 | $2,626,288 |
Totals as disclosed in each year's own compensation disclosure for Karyopharm Therapeutics Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Richard Paulson this page | President and Chief Executive Officer | $2,320,902 |
| Reshma Rangwala | Executive Vice President, Chief Medical Officer and Head of Research | $2,016,134 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | $1,399,580 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Karyopharm Therapeutics Inc. compensation brief.
Richard Paulson's compensation sits inside Karyopharm Therapeutics Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.